CN114159422A - Application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine absorption capacity - Google Patents
Application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine absorption capacity Download PDFInfo
- Publication number
- CN114159422A CN114159422A CN202111535693.0A CN202111535693A CN114159422A CN 114159422 A CN114159422 A CN 114159422A CN 202111535693 A CN202111535693 A CN 202111535693A CN 114159422 A CN114159422 A CN 114159422A
- Authority
- CN
- China
- Prior art keywords
- parts
- reaction
- magnesium
- water
- linolenic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/76—Metal complexes of amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a magnesium-containing water-soluble omega 3 fatty acid, and relates to the technical field of omega 3 fatty acids. The magnesium-containing water-soluble omega 3 fatty acid provided by the invention is modified alpha-linolenic acid, can be dissolved in water by modification, and can effectively promote the length of villus of the small intestine, so that the digestion and absorption functions of the small intestine are enhanced. In addition, the omega 3 fatty acid provided by the invention can supplement magnesium element while supplementing alpha-linolenic acid.
Description
The scheme is a divisional application, and the original application name is as follows: a magnesium-containing water-soluble omega 3 fatty acid is disclosed as follows: 2021-09-29, the application number of the original application is: CN 202111150908.7.
Technical Field
The invention relates to the technical field of omega 3 fatty acid, in particular to application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine absorption capacity.
Background
Omega 3 fatty acid is an unsaturated fatty acid, which has an adverse effect on health, whereas as a polyunsaturated fatty acid omega 3 fatty acid has many health benefits. Different types of evidence suggest that reduced omega 3 fatty acid concentrations can cause mood disorders. Some preliminary results suggest that it is effective in treating various psychiatric disorders such as bipolar disorder, schizophrenia, dementia, and is a safe and effective therapeutic agent for pregnant and lactating women.
At present, omega 3 fatty acid mostly adopts a capsule type, has single function, has less research on water-soluble omega 3 fatty acid, and is difficult to modify according to additional functions because modification conditions and used reagents are harsh when the omega 3 fatty acid is modified.
Disclosure of Invention
The invention aims to provide a magnesium-containing water-soluble omega 3 fatty acid which can supplement magnesium and promote the development of intestinal villi.
In order to achieve the purpose, the invention provides a magnesium-containing water-soluble omega 3 fatty acid, wherein the magnesium-containing water-soluble omega 3 fatty acid is modified alpha-linolenic acid, and the chemical formula of the modified alpha-linolenic acid is as follows:
preferably, the preparation steps of the modified alpha-linolenic acid are as follows:
weighing 10-20 parts of alanine, 5-15 parts of magnesium carbonate and 200 parts of water according to parts by weight;
preparing a mixed solution A from alanine, magnesium carbonate and water, adjusting the pH value to 3-5, putting the mixed solution A into a reaction kettle with a stirring function, continuously stirring at the rotating speed of 300-500r/min in the reaction process, setting reaction conditions, cooling, filtering, removing distilled water from the filtrate by using a rotary evaporator to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain alanine chelated magnesium, wherein the reaction process for preparing the alanine chelated magnesium is as follows:
weighing 10-20 parts of alanine chelated magnesium, 10-20 parts of cinnamic acid, 3-5 parts of benzophenone and 50-100 parts of water according to parts by weight, mixing to prepare a mixed solution B, putting the mixed solution B into a reaction kettle with a stirring function, continuously stirring at the stirring speed of 200-500r/min in the reaction process, setting reaction conditions, cooling and rotationally evaporating to remove water after the reaction is finished to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain a cinnamic acid derivative A, wherein the reaction process for preparing the cinnamic acid derivative A is as follows:
weighing 30-50 parts of alpha-linolenic acid, 20-30 parts of cinnamic acid derivative A, 5-10 parts of magnesium sulfate, 5-10 parts of dibutyl terephthalate and 200 parts of water according to parts by weight, putting the materials into an emulsifying machine at the rotating speed of 500-2000r/min for 10-30min, preparing emulsion A, putting the emulsion A into a container, putting the container into a microwave oven, setting reaction conditions, filtering by using a sand core funnel after the reaction is finished, removing water by using a rotary evaporator, purifying a crude product by using a column chromatography method, and finally drying in vacuum to obtain the modified alpha-linolenic acid, wherein the reaction process for preparing the modified alpha-linolenic acid is as follows:
preferably, the first and second liquid crystal materials are,
in the step (2) of preparing the modified alpha-linolenic acid, the reaction conditions are that the temperature of the reaction kettle is 80-100 ℃, and the reaction time is 1-2 h;
in the step (3) of preparing the modified alpha-linolenic acid, the reaction conditions are that the temperature of the reaction kettle is 80-120 ℃, and the reaction time is 5-8 h;
in the step (4) for preparing the modified alpha-linolenic acid, the reaction conditions are that the power of a microwave oven is adjusted to 2000-2500W, and the treatment time is 0.5-1 min.
Secondly, the invention provides an application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine villus development, wherein the magnesium-containing water-soluble omega 3 fatty acid is modified alpha-linolenic acid, and the chemical formula of the modified alpha-linolenic acid is as follows:
the preparation steps of the modified alpha-linolenic acid are as follows:
weighing 10-20 parts of alanine, 5-15 parts of magnesium carbonate and 200 parts of water according to parts by weight;
preparing a mixed solution A from alanine, magnesium carbonate and water, adjusting the pH value to 3-5, putting the mixed solution A into a reaction kettle with a stirring function, continuously stirring at the rotating speed of 300-500r/min in the reaction process, setting reaction conditions, cooling, filtering, removing distilled water from the filtrate by using a rotary evaporator to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain alanine chelated magnesium, wherein the reaction process for preparing the alanine chelated magnesium is as follows:
weighing 10-20 parts of alanine chelated magnesium, 10-20 parts of cinnamic acid, 3-5 parts of benzophenone and 50-100 parts of water according to parts by weight, mixing to prepare a mixed solution B, putting the mixed solution B into a reaction kettle with a stirring function, continuously stirring at the stirring speed of 200-500r/min in the reaction process, setting reaction conditions, cooling and rotationally evaporating to remove water after the reaction is finished to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain a cinnamic acid derivative A, wherein the reaction process for preparing the cinnamic acid derivative A is as follows:
weighing 30-50 parts of alpha-linolenic acid, 20-30 parts of cinnamic acid derivative A, 5-10 parts of magnesium sulfate, 5-10 parts of dibutyl terephthalate and 200 parts of water according to parts by weight, putting the materials into an emulsifying machine at the rotating speed of 500-2000r/min for 10-30min, preparing emulsion A, putting the emulsion A into a container, putting the container into a microwave oven, setting reaction conditions, filtering by using a sand core funnel after the reaction is finished, removing water by using a rotary evaporator, purifying a crude product by using a column chromatography method, and finally drying in vacuum to obtain the modified alpha-linolenic acid, wherein the reaction process for preparing the modified alpha-linolenic acid is as follows:
in the step (2) for preparing the modified alpha-linolenic acid, the reaction conditions are that the temperature of the reaction kettle is 80-100 ℃, and the reaction time is 1-2 h;
in the step (3) for preparing the modified alpha-linolenic acid, the reaction conditions are that the temperature of the reaction kettle is 80-120 ℃, and the reaction time is 5-8 h;
in the step (4) for preparing the modified alpha-linolenic acid, the reaction conditions are that the power of a microwave oven is adjusted to 2000-2500W, and the treatment time is 0.5-1 min.
The invention has the beneficial effects that:
the omega 3 fatty acid disclosed by the invention can be quickly dissolved in water, can be directly brewed with water for drinking, and is beneficial to gastrointestinal absorption.
The omega 3 fatty acid disclosed by the invention can supplement magnesium element while supplementing alpha-linolenic acid.
Drawings
FIG. 1 water solubility profiles of different experimental groups.
FIG. 2 shows the villus height change of the ileum and small intestine of mice in different experimental groups.
FIG. 3 shows the change in the villus height of the jejunum and small intestine of mice in different experimental groups.
Detailed Description
In order to clearly illustrate the technical features of the present solution, the present solution is explained below by way of specific embodiments.
Example 1:
weighing 10 parts of alanine, 5 parts of magnesium carbonate and 150 parts of water according to parts by weight;
preparing a mixed solution A from alanine, magnesium carbonate and water, adjusting the pH value to 3, putting the mixed solution A into a reaction kettle with a stirring function, setting the rotating speed of a stirrer to be 300r/min, continuously stirring in the reaction process, setting the temperature of the reaction kettle to be 80 ℃, reacting for 1h, cooling, filtering, removing distilled water from filtrate by using a rotary evaporator to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain the alanine chelated magnesium.
Weighing 10 parts of alanine chelated magnesium, 10 parts of cinnamic acid, 3 parts of benzophenone and 50 parts of water according to parts by weight, mixing to prepare a mixed solution B, putting the mixed solution B into a reaction kettle with a stirring function, setting the rotation speed of a stirrer to be 200r/min, continuously stirring in the reaction process, setting the temperature of the reaction kettle to be 80 ℃, setting the reaction time to be 5 hours, cooling and carrying out rotary evaporation on water after the reaction is finished to obtain a crude product, carrying out column chromatography separation and purification on the crude product, and finally carrying out vacuum drying to obtain the cinnamic acid derivative A.
Weighing 30 parts of alpha-linolenic acid, 20 parts of cinnamic acid derivative A, 5 parts of magnesium sulfate, 5 parts of dibutyl terephthalate and 100 parts of water according to parts by weight, putting the weighed materials into an emulsifying machine, setting the rotating speed of the emulsifying machine at 500r/min and the emulsifying time at 10min, preparing emulsion A, putting the emulsion A into a container, putting the container into a microwave oven, setting the power of the microwave oven at 2000W and the processing time at 0.5min, filtering by using a sand core funnel after the reaction is finished, removing water by using a rotary evaporator, purifying a crude product by using a column chromatography method, and finally drying in vacuum to obtain the modified alpha-linolenic acid.
Example 2:
weighing 20 parts of alanine, 15 parts of magnesium carbonate and 200 parts of water according to parts by weight.
Preparing a mixed solution A from alanine, magnesium carbonate and water, adjusting the pH value to 5, putting the mixed solution A into a reaction kettle with a stirring function, setting the rotating speed of a stirrer to be 500r/min, continuously stirring in the reaction process, setting the temperature of the reaction kettle to be 100 ℃, reacting for 2 hours, cooling, filtering, removing distilled water from filtrate by using a rotary evaporator to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain the alanine chelated magnesium.
Weighing 20 parts of alanine chelated magnesium, 20 parts of cinnamic acid, 5 parts of benzophenone and 100 parts of water according to parts by weight, mixing to prepare a mixed solution B, putting the mixed solution B into a reaction kettle with a stirring function, setting the rotation speed of a stirrer to be 500r/min, continuously stirring in the reaction process, setting the temperature of the reaction kettle to be 120 ℃, setting the reaction time to be 8 hours, cooling and carrying out rotary evaporation on water after the reaction is finished to obtain a crude product, carrying out column chromatography separation and purification on the crude product, and finally carrying out vacuum drying to obtain the cinnamic acid derivative A.
Weighing 50 parts of alpha-linolenic acid, 30 parts of cinnamic acid derivative A, 10 parts of magnesium sulfate, 10 parts of dibutyl terephthalate and 200 parts of water according to parts by weight, putting the weighed materials into an emulsifying machine, setting the rotating speed of the emulsifying machine at 2000r/min and the emulsifying time at 30min, preparing emulsion A, putting the emulsion A into a container, putting the container into a microwave oven, setting the power of the microwave oven at 2500W and the processing time at 1min, filtering by using a sand core funnel after the reaction is finished, removing water by using a rotary evaporator, purifying the crude product by using a column chromatography method, and finally drying in vacuum to obtain the modified alpha-linolenic acid.
Example 3:
weighing 15 parts of alanine, 10 parts of magnesium carbonate and 180 parts of water according to parts by weight.
Preparing a mixed solution A from alanine, magnesium carbonate and water, adjusting the pH value to 4, putting the mixed solution A into a reaction kettle with a stirring function, setting the rotating speed of a stirrer to be 400r/min, continuously stirring in the reaction process, setting the temperature of the reaction kettle to be 90 ℃, setting the reaction time to be 1.5h, cooling, carrying out suction filtration, removing distilled water from the filtrate by using a rotary evaporator to obtain a crude product, separating and purifying the crude product by using column chromatography, and finally carrying out vacuum drying to obtain the alanine chelated magnesium.
Weighing 15 parts of alanine chelated magnesium, 15 parts of cinnamic acid, 4 parts of benzophenone and 70 parts of water according to parts by weight, mixing to prepare a mixed solution B, putting the mixed solution B into a reaction kettle with a stirring function, setting the rotation speed of a stirrer to be 300r/min, continuously stirring in the reaction process, setting the temperature of the reaction kettle to be 100 ℃, setting the reaction time to be 6 hours, cooling and carrying out rotary evaporation on water after the reaction is finished to obtain a crude product, carrying out column chromatography separation and purification on the crude product, and finally carrying out vacuum drying to obtain the cinnamic acid derivative A.
Weighing 40 parts of alpha-linolenic acid, 25 parts of cinnamic acid derivative A, 7 parts of magnesium sulfate, 7 parts of dibutyl terephthalate and 130 parts of water according to parts by weight, putting the weighed materials into an emulsifying machine, setting the rotating speed of the emulsifying machine at 1500r/min, setting the emulsifying time at 20min, preparing emulsion A, putting the emulsion A into a container, putting the container into a microwave oven, setting the power of the microwave oven at 2200W, setting the processing time at 0.8min, filtering by using a sand core funnel after the reaction is finished, removing water by using a rotary evaporator, purifying a crude product by using a column chromatography method, and finally drying in vacuum to obtain the modified alpha-linolenic acid.
The modified α -linolenic acids prepared in examples 1 to 3 were subjected to magnesium ion concentration test (titration method), water solubility test and animal test.
(1) The magnesium ion concentration test method comprises the following steps:
5g of the modified alpha-linolenic acids prepared in examples 1 to 3 were weighed and chargedAdding into 20ml water, and detecting Mg with magnesium ion detector2+The contents and specific results are shown in Table 1.
(2) Water solubility test method:
30g of alpha-linolenic acid and the modified alpha-linolenic acid prepared in examples 1 to 3 were weighed, and the weighed alpha-linolenic acid and modified alpha-linolenic acid were put into 100g of water, and stirred with a glass rod for 1min to observe the dissolution.
(3) Animal experiments:
grouping and animal feeding:
selecting 25 mice with similar weights, and randomly dividing the mice into 5 groups, wherein each group comprises 5 mice;
respectively weighing 10g of the modified alpha-linolenic acid prepared in the embodiment 1 to 3, and respectively putting the modified alpha-linolenic acid into 50g of water for dissolving, wherein the solution is marked as solution A, solution B and solution C;
weighing 70g of each of 5 parts of feed, mixing the feed with 50g of water, the prepared solution A, the prepared solution B and the prepared solution C respectively, and marking the feed as contrast 1, the feed A, the feed B and the feed C; weighing 10g of alpha-linolenic acid and 50g of water, mixing the rest 1 part of feed, the alpha-linolenic acid and the water together, and marking as a control 2 feed;
and fourthly, feeding the mice in 5 groups with drinking water and feed according to the following table in a fixed time and fixed amount for 4 weeks.
TABLE 1 feeding method
Tissue collection and detection:
after the mice were fed for 4 weeks, the daily ration was stopped and only the mice were given drinking water. The mice are fasted for 12 hours before being killed, the cervical vertebra is cut off to die, and the small intestinal tissues in the bodies of the mice are quickly taken out. Each group of mice takes a jejunum and an ileum section with the length of about 2cm, the contents are washed clean by normal saline, an intestinal canal is fixed by 10 percent formaldehyde phosphate buffer solution, tissues are fixed for more than 6h, the fixed specimens are dehydrated and transparent by 4 concentration gradients (75 percent, 85 percent, 95 percent and 100 percent) of alcohol and xylene, a Leica RM2235 microtome and an ZMN-7803 full-automatic tissue embedding machine are used for preparing paraffin sections, and finally, the sections are stained by a hematoxylin-eosin staining method. Images were taken using a photomicrograph device and the length of the villus was measured using the Mot-ic images 20001.3 software, the results of which are shown in table 2 and the accompanying drawings.
TABLE 2 test results
TABLE 3 test results
As can be seen in Table 2, examples 1-3 all contained magnesium ions, indicating that magnesium ions were successfully grafted onto alpha-linolenic acid after the modification of alpha-linolenic acid by examples 1-3.
As can be seen from comparison of # 1-3 with control group 1 and control group 2 in Table 3 and FIGS. 2-3, the ileum villus length of mice drinking nutrient water is increased by about 20-40% compared with control group 1 and control group 2, and the jejunum villus length is also increased by about 20-40%, so that the modified alpha-linolenic acid prepared in examples 1-3 has the function of increasing the villus length of small intestine, and the function of enhancing the digestion and absorption capacity of small intestine on the modified alpha-linolenic acid disclosed by the invention is reflected from the side face.
Claims (4)
1. The application of magnesium-containing water-soluble omega 3 fatty acid in promoting the development of intestinal villi is characterized in that the magnesium-containing water-soluble omega 3 fatty acid is modified alpha-linolenic acid, and the chemical formula of the modified alpha-linolenic acid is as follows:
2. use according to claim 1, characterized in that the modified alpha-linolenic acid is prepared by the following steps:
weighing 10-20 parts of alanine, 5-15 parts of magnesium carbonate and 200 parts of water according to parts by weight;
preparing a mixed solution A from alanine, magnesium carbonate and water, adjusting the pH value to 3-5, putting the mixed solution A into a reaction kettle with a stirring function, continuously stirring at the rotating speed of 300-500r/min in the reaction process, setting reaction conditions, cooling, filtering, removing distilled water from the filtrate by using a rotary evaporator to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain alanine chelated magnesium, wherein the reaction process for preparing the alanine chelated magnesium is as follows:
weighing 10-20 parts of alanine chelated magnesium, 10-20 parts of cinnamic acid, 3-5 parts of benzophenone and 50-100 parts of water according to parts by weight, mixing to prepare a mixed solution B, putting the mixed solution B into a reaction kettle with a stirring function, continuously stirring at the stirring speed of 200-500r/min in the reaction process, setting reaction conditions, cooling and rotationally evaporating to remove water after the reaction is finished to obtain a crude product, separating and purifying the crude product by column chromatography, and finally drying in vacuum to obtain a cinnamic acid derivative A, wherein the reaction process for preparing the cinnamic acid derivative A is as follows:
weighing 30-50 parts of alpha-linolenic acid, 20-30 parts of cinnamic acid derivative A, 5-10 parts of magnesium sulfate, 5-10 parts of dibutyl terephthalate and 200 parts of water according to parts by weight, putting the materials into an emulsifying machine at the rotating speed of 500-2000r/min for 10-30min, preparing emulsion A, putting the emulsion A into a container, putting the container into a microwave oven, setting reaction conditions, filtering by using a sand core funnel after the reaction is finished, removing water by using a rotary evaporator, purifying a crude product by using a column chromatography method, and finally drying in vacuum to obtain the modified alpha-linolenic acid, wherein the reaction process for preparing the modified alpha-linolenic acid is as follows:
3. use according to claim 2,
in the step (2), the reaction conditions are that the temperature of the reaction kettle is 80-100 ℃, and the reaction time is 1-2 h;
in the step (3), the reaction conditions are that the temperature of the reaction kettle is 80-120 ℃, and the reaction time is 5-8 h;
in the step (4), the reaction conditions are that the microwave power is adjusted to 2000-2500W, and the treatment time is 0.5-1 min.
4. The use according to claim 1, wherein the small intestine comprises the jejunum and ileum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111535693.0A CN114159422B (en) | 2021-09-29 | 2021-09-29 | Application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine absorption capacity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111150908.7A CN113582871B (en) | 2021-09-29 | 2021-09-29 | Magnesium-containing water-soluble omega 3 fatty acid |
| CN202111535693.0A CN114159422B (en) | 2021-09-29 | 2021-09-29 | Application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine absorption capacity |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111150908.7A Division CN113582871B (en) | 2021-09-29 | 2021-09-29 | Magnesium-containing water-soluble omega 3 fatty acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114159422A true CN114159422A (en) | 2022-03-11 |
| CN114159422B CN114159422B (en) | 2023-02-28 |
Family
ID=78242503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111535693.0A Active CN114159422B (en) | 2021-09-29 | 2021-09-29 | Application of magnesium-containing water-soluble omega 3 fatty acid in promoting small intestine absorption capacity |
| CN202111150908.7A Active CN113582871B (en) | 2021-09-29 | 2021-09-29 | Magnesium-containing water-soluble omega 3 fatty acid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111150908.7A Active CN113582871B (en) | 2021-09-29 | 2021-09-29 | Magnesium-containing water-soluble omega 3 fatty acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114159422B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114469988B (en) * | 2022-03-01 | 2022-08-16 | 北京天赋神奇科技有限公司 | Biological preparation containing water-soluble fatty acid and trichosanthes bark polysaccharide |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
| CN102105436A (en) * | 2008-04-21 | 2011-06-22 | 罗伯托·贝尔尼卡纳尼 | Fatty acid derivatives for oral administration endowed with high paia- tability |
| CN102241633A (en) * | 2011-05-24 | 2011-11-16 | 王沁 | Linolenic acid-carnosine composite and preparation method thereof |
| CN102573496A (en) * | 2009-07-01 | 2012-07-11 | 玛格塞蒂克斯公司 | Slow release magnesium composition and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010151816A1 (en) * | 2009-06-26 | 2010-12-29 | Eric Kuhrts | Water-soluble dietary fatty acids |
| US10150792B2 (en) * | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| WO2015137357A1 (en) * | 2014-03-10 | 2015-09-17 | サラヤ株式会社 | Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition |
| CN111718272B (en) * | 2020-07-14 | 2023-09-19 | 安徽华恒生物科技股份有限公司 | Preparation method and application of alanine metal chelate |
| CN111995535A (en) * | 2020-08-04 | 2020-11-27 | 巴彦淖尔华恒生物科技有限公司 | Preparation method and application of alanine metal chelate |
-
2021
- 2021-09-29 CN CN202111535693.0A patent/CN114159422B/en active Active
- 2021-09-29 CN CN202111150908.7A patent/CN113582871B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
| CN102105436A (en) * | 2008-04-21 | 2011-06-22 | 罗伯托·贝尔尼卡纳尼 | Fatty acid derivatives for oral administration endowed with high paia- tability |
| CN102573496A (en) * | 2009-07-01 | 2012-07-11 | 玛格塞蒂克斯公司 | Slow release magnesium composition and uses thereof |
| CN102241633A (en) * | 2011-05-24 | 2011-11-16 | 王沁 | Linolenic acid-carnosine composite and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| JACQUES GORE ET AL.: "Linolenic Acid Transport in Hamster Intestinal Cells Is Carrier-Mediated", 《NUTRIENT METABOLISM》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113582871A (en) | 2021-11-02 |
| CN114159422B (en) | 2023-02-28 |
| CN113582871B (en) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113582871B (en) | Magnesium-containing water-soluble omega 3 fatty acid | |
| WO1992017599A1 (en) | Cma production utilizing acetate ion exchange from fermentation broth | |
| EP3208259B1 (en) | Preparation method for polyunsaturated fatty acid-calcium | |
| US5099001A (en) | Process for the production of thyroglobulin | |
| CN113083253B (en) | Weak acid cation resin for extracting vitamin B12 and synthetic method thereof | |
| JPH07110209B2 (en) | Gelatin manufacturing method | |
| CN107286071B (en) | A method of extracting bilirubin and cholic acid co-production cholesterol, lecithin from bile | |
| CN1137629C (en) | Continuous technolgical process of extracting soybean and separating protein, isoflavone, oligosaccharide and saponin | |
| CN1060156C (en) | Production method for calcium acetate | |
| CN110105195A (en) | A method of extracting dihydroartemisinic acid from sweet wormwood wax oil | |
| CN1057255A (en) | Utilize tower to draw powder to produce gallic acid | |
| CN111362821B (en) | Environment-friendly and efficient levodopa production method | |
| CN1054788A (en) | Process for extracting grease and tea saponin by one-step leaching of cake dregs | |
| CN109280015A (en) | A kind of synthesis of D-VB5 sodium and chiral separation method | |
| CN114735738A (en) | Production process of iron-free high-purity aluminum sulfate | |
| CN1076362A (en) | The preparation method of royal jelly oral products | |
| CN107400175A (en) | A kind of preparation method of high-purity peach gum | |
| CN86105966A (en) | The method of extracting pectin from beencard firewood leaves | |
| CN114214514A (en) | Method for leaching and removing phosphorus in high-phosphorus calcine roasting vanadium-containing clinker and recycling leachate | |
| CN113861018A (en) | Purification treatment method of citric acid mother liquor | |
| CN106749437A (en) | A kind of recovery method of Glucosamine Sulphate sodium chloride double salt mother liquor | |
| CN108864323A (en) | The extraction process of chitin in a kind of shrimp shell slag | |
| CN110002489A (en) | A kind of preparation method of superfine powder state basic copper chloride | |
| CN101921000A (en) | Production method of pharmaceutical-grade ferrous sulfate | |
| CN117777428A (en) | Purification method and system of polyether surfactant based on mannitol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |